This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
This week I’m posting another interview with Dr. Anthony Mato from UPenn when we talked at ASH 2016 about the optimal sequencing of ibrutinib, idelalisib, and venetoclax. He has been doing real-world research collecting data from patients being treated both in the community and academic settings, and not just within clinical trials. You can view my summary and watch the interview here.
CLL Patient Support Group Meetings This Week
Thursday, June 1st at 7 PM in New City, NY – The CLL Information & Support Group of Rockland County NY, sponsored by LLS will be meeting. More information here.
Monday, June 5th at 6 PM in Indianapolis, IN – The CLL and Indolent Blood Cancers Support Group, sponsored by LLS will be meeting. More information here.
ALSO – We are actively forming CLL-specific support groups in a number of cities around the country. To see if your city is one of them, click here and select the interest survey for your city. JUST ADDED – Hartford, CT and Nashville, TN. Not listed, but interested in starting one? Email us at email@example.com Thanks!
In the meantime….
We are all in this together.
Brian Koffman, MD